Retinoids and pregnancy: an update. (January 2014)

• Record Type: Journal Article
• Authors: Browne, Hannah; Mason, Gerald; Tang, Thomas
• Is Part Of: Obstetrician & gynaecologist. Volume 16:Number 1(2014)
• Page Start: 7
• Page End: 11
• Publication Date: 2014-01
• Subjects: Obstetrics -- Periodicals; Gynecology -- Periodicals; 618
• DOI: 10.1111/tog.12075
• Languages: English
• ISSNs: 1467-2561

Abstract

<abstract abstract-type="main" id="tog12075-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="tog12075-sec-0001" sec-type="section"> <title>Key content</title> <p> <list id="tog12075-list-0001" list-type="bullet"> <list-item> <p>The use and pharmacokinetics of retinoids.</p> </list-item> <list-item> <p>The main known teratogenic effects of retinoids are face, skull, cardiovascular, nervous system and thymic abnormalities.</p> </list-item> <list-item> <p>The pregnancy prevention programme must be adhered to when initiating retinoid treatment.</p> </list-item> <list-item> <p>Effective contraception should be continued for at least one month after cessation of retinoid treatment.</p> </list-item> <list-item> <p>Management options of pregnant women with recent retinoid use or exposure in early pregnancy; including involvement of the specialist multidisciplinary team.</p> </list-item> </list> </p> </sec> <sec id="tog12075-sec-0002" sec-type="section"> <title>Learning objectives</title> <p> <list id="tog12075-list-0002" list-type="bullet"> <list-item> <p>To understand the risk and in particular teratogenesis associated with exposure to retinoids peri‐conception.</p> </list-item> <list-item> <p>To raise awareness of the pregnancy prevention programme.</p> </list-item> <list-item> <p>To highlight the management options for women who become pregnant with recent retinoid use or exposure in early pregnancy.</p> </list-item> </list> </p> </sec> <sec id="tog12075-sec-0003" sec-type="section"> <title>Ethical issues</title> <p> <list id="tog12075-list-0003" list-type="bullet"> <list-item> <p>Termination of pregnancy with peri‐conceptual exposure to retinoids.</p> </list-item> <list-item> <p>Should isotretinoin be used so widely in the childbearing population when we are aware of its teratogenicity?</p> </list-item> </list> </p> </sec> </abstract>